Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance
Erik S.G. Stroes(Amsterdam University Medical Centers), Michael Rocco(Cleveland Clinic), Allen Xue(Amgen (United States)), Leslie Cho(Cleveland Clinic), Éric Bruckert(Centre de Recherche Médecine, Sciences, Santé, Santé Mentale, Société), Robert S. Rosenson(Mount Sinai Hospital), Robert C. Scott(Amgen (United States)), David Sullivan(Royal Prince Alfred Hospital), Fernando Civeira(Universidad de Zaragoza), Gerald F. Watts(Royal Perth Hospital), Scott M. Wasserman(Amgen (United States)), David Colquhoun(University College London), Ricardo Dent(Amgen (United States)), Beat Knüsel(Amgen (United States))
Cited by 527
Related Papers
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
|New England Journal of Medicine|2017|6k
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
|European Heart Journal|2017|3.8k
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society
|European Heart Journal|2013|2.7k
Lipoprotein(a) as a cardiovascular risk factor: current status
|European Heart Journal|2010|1.8k